Completed
Safety and Pharmacokinetics of L-Ofloxacin in HIV-Positive Patients
What is being tested
Levofloxacin
Drug
Who is being recruted
Blood-Borne Infections+13
+ Urogenital Diseases
+ Genital Diseases
Over 18 Years
+10 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 1
Interventional
Summary
Principal SponsorR W Johnson Pharmaceutical Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
This study is about exploring the safety and how the body processes a drug called L-Ofloxacin (RWJ 25213) in individuals who have HIV infection. The goal is to understand if this drug can be a potential treatment option for those living with HIV. It's important to conduct this research as it may pave the way for new treatments and improve the quality of care for HIV patients.
Principal SponsorR W Johnson Pharmaceutical Research Institute
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Male
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsAcquired Immunodeficiency SyndromeHIV Infections
Criteria
1 inclusion criteria required to participate
HIV infection
9 exclusion criteria prevent from participating
Active opportunistic infection or neoplasm
Alcohol or drug abuse
Donation of > 1 unit blood or acute loss of blood within one month of study entry
High likelihood of death during study
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
R W Johnson Pharmaceutical Research Institute
Raritan, United StatesOpen R W Johnson Pharmaceutical Research Institute in Google MapsCompletedOne Study Center